CL2023002956A1 - Inhibidor de la proteasa 1 específica de ubiquitina (usp1) - Google Patents

Inhibidor de la proteasa 1 específica de ubiquitina (usp1)

Info

Publication number
CL2023002956A1
CL2023002956A1 CL2023002956A CL2023002956A CL2023002956A1 CL 2023002956 A1 CL2023002956 A1 CL 2023002956A1 CL 2023002956 A CL2023002956 A CL 2023002956A CL 2023002956 A CL2023002956 A CL 2023002956A CL 2023002956 A1 CL2023002956 A1 CL 2023002956A1
Authority
CL
Chile
Prior art keywords
usp1
ubiquitin
inhibitor
specific protease
compounds
Prior art date
Application number
CL2023002956A
Other languages
English (en)
Inventor
Berry Loren
Joseph Buckmelter Alexandre
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of CL2023002956A1 publication Critical patent/CL2023002956A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción provee compuestos para inhibir USP1, y los métodos relacionados para preparar y utilizar los compuestos.
CL2023002956A 2021-04-07 2023-10-03 Inhibidor de la proteasa 1 específica de ubiquitina (usp1) CL2023002956A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163171796P 2021-04-07 2021-04-07

Publications (1)

Publication Number Publication Date
CL2023002956A1 true CL2023002956A1 (es) 2024-03-08

Family

ID=83546542

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002956A CL2023002956A1 (es) 2021-04-07 2023-10-03 Inhibidor de la proteasa 1 específica de ubiquitina (usp1)

Country Status (13)

Country Link
US (1) US20240239808A1 (es)
EP (1) EP4319758A1 (es)
JP (1) JP2024514322A (es)
KR (1) KR20230167071A (es)
CN (1) CN117241801A (es)
AU (1) AU2022254062A1 (es)
BR (1) BR112023019075A2 (es)
CA (1) CA3214040A1 (es)
CL (1) CL2023002956A1 (es)
IL (1) IL307157A (es)
MA (1) MA62912A1 (es)
MX (1) MX2023011709A (es)
WO (1) WO2022216820A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202327602A (zh) * 2021-11-12 2023-07-16 香港商英科智能有限公司 泛素特異性蛋白酶1 (usp1)之小分子抑制劑及其用途
KR20240117556A (ko) 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
KR20240117555A (ko) * 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
CN118525022A (zh) * 2022-01-27 2024-08-20 西藏海思科制药有限公司 一种氮杂并环衍生物及其在医药上的应用
WO2023148643A1 (en) * 2022-02-03 2023-08-10 Aurigene Oncology Limited Fused bicyclic heterocyclyl compounds as usp1 inhibitors
CN118660872A (zh) * 2022-04-29 2024-09-17 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
CN117003757A (zh) * 2022-05-07 2023-11-07 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2024006879A1 (en) * 2022-06-29 2024-01-04 Zentaur Therapeutics Usa Inc. Usp1 inhibitors and uses thereof
WO2024022266A1 (en) * 2022-07-25 2024-02-01 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heteroaryl compounds as inhibitors of usp1
WO2024032647A1 (zh) * 2022-08-09 2024-02-15 上海济煜医药科技有限公司 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
TW202411231A (zh) * 2022-09-09 2024-03-16 大陸商正大天晴藥業集團股份有限公司 用作泛素-特異性蛋白酶抑制劑的取代嘌呤酮衍生物
TW202421624A (zh) * 2022-09-20 2024-06-01 大陸商正大天晴藥業集團股份有限公司 用作泛素－特異性蛋白酶抑制劑的羰基稠合雜環衍生物
WO2024078436A1 (zh) * 2022-10-09 2024-04-18 海南先声再明医药股份有限公司 杂环并嘧啶类化合物、药物组合物及其应用
WO2024153175A1 (en) * 2023-01-19 2024-07-25 Laekna Therapeutics Shanghai Co., Ltd. Heteroaromatic compounds and their use as usp1 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137320A2 (en) * 2010-04-30 2011-11-03 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
AU2013370417A1 (en) * 2012-12-28 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
BR112018010216B1 (pt) * 2015-11-20 2024-02-15 Forma Therapeutics, Inc Purinonas como inibidores da protease específica da ubiquitina 1 e composição farmacêutica compreendendo os referidos compostos
TW202421630A (zh) * 2018-12-20 2024-06-01 美商Ｋｓｑ治療公司 經取代之吡唑并嘧啶及經取代之嘌呤以及其作為泛素特異性加工蛋白酶１（ｕｓｐ１）抑制劑的用途
US20220073525A1 (en) * 2018-12-28 2022-03-10 Forma Therapeutics, Inc. Compositions for inhibiting ubiquitin specific protease 1

Also Published As

Publication number Publication date
MA62912A1 (fr) 2024-05-31
WO2022216820A1 (en) 2022-10-13
CN117241801A (zh) 2023-12-15
JP2024514322A (ja) 2024-04-01
MX2023011709A (es) 2023-10-12
AU2022254062A1 (en) 2023-10-12
IL307157A (en) 2023-11-01
BR112023019075A2 (pt) 2023-10-17
CA3214040A1 (en) 2022-10-13
KR20230167071A (ko) 2023-12-07
EP4319758A1 (en) 2024-02-14
US20240239808A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
CL2023002956A1 (es) Inhibidor de la proteasa 1 específica de ubiquitina (usp1)
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
CL2021002880S1 (es) Estuche de auriculares. (divisional solicitud 202000595)
CO2021016018A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
MX2021012589A (es) Derivados de piperidina como inhibidores de proteasa especifica de ubiquitina 7.
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
DOP2015000014A (es) Derivados de azaadamantano y metodos de uso de los mismos
UY38837A (es) Proceso de elaboración de moduladores de cftr
CR9272A (es) Amino-imidazolonas para la inhibicion de b-secretasa
UY29176A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos.
CO2024006279A2 (es) Inhibidores de molécula pequeña de proteasa específica de ubiquitina 1 (usp1) y usos de los mismos
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
UY27894A1 (es) Derivados de cinamida.
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
AR119677A1 (es) Dominios de unión anti-cd38
CO2021012375A2 (es) Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo
CO2020001861A2 (es) Inhibidores de ror gamma
CO2024006269A2 (es) Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
CO2023015915A2 (es) Anticuerpos anti-ccr8
CO2022000266A2 (es) Inhibidores de enzimas
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
CL2021003373A1 (es) Nuevos inhibidores de egfr
ZA202106519B (en) Caspase inhibitors and methods of use thereof